Skip to main content
Kolon TissueGene, Inc. logo

Kolon TissueGene, Inc. — Investor Relations & Filings

Ticker · 950160 ISIN · KR8840120008 LEI · 5493000SYYLC88FUL781 KO Manufacturing
Open in API
Filings indexed 288 across all filing types
Latest filing 2025-03-07 Remuneration Information
Country US United States of America
Listing KO 950160

About Kolon TissueGene, Inc.

https://www.tissuegene.com/

Kolon TissueGene, Inc. is a clinical-stage biopharmaceutical company specializing in the development of advanced cell and gene therapies for orthopedic diseases and degenerative disorders. The company's lead product candidate, TG-C, is a first-in-class, allogeneic cell and gene therapy designed to treat knee osteoarthritis. The therapy aims to reduce pain, improve joint function, and slow the progression of the disease. TG-C is currently in late-stage clinical development, undergoing Phase 3 trials.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Remuneration Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the board resolution, the number of shares, exercise price, and the list of recipients (employees). This type of disclosure is a standard regulatory requirement for listed companies in Korea to report changes in capital structure or equity-based compensation, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2025-03-07 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Kolon TissueGene, Inc. It contains the meeting agenda, voting procedures, director activity reports, and business overview. This document is a standard proxy statement/notice sent to shareholders to inform them of the upcoming AGM and solicit their votes, which aligns with the definition of a Proxy Solicitation & Information Statement.
2025-03-07 Korean
[첨부추가]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Kolon TissueGene. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and compensation limits). This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-03-07 Korean
증권발행결과(자율공시) (제3회차 CB)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (specifically a convertible bond, or CB). It details the issuance amount, payment date, and the nature of the securities. This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments.
2025-02-26 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from Kolon TissueGene, Inc. regarding the issuance of convertible bonds (전환사채권 발행결정). It details the terms of the bond, including interest rates, conversion prices, maturity dates, and the use of proceeds. This type of filing is a standard regulatory disclosure for capital raising activities in the Korean market, which falls under the 'Capital/Financing Update' category.
2025-02-19 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from Kolon TissueGene regarding a significant change (over 30%) in revenue or profit/loss structure. This is a standard mandatory disclosure filing in the Korean market (DART system) used to announce preliminary financial results before the final audited annual report is published. It provides key financial highlights, reasons for the variance, and a disclaimer that it is pre-audit. This fits the 'Earnings Release' (ER) category as it serves as the initial announcement of financial performance. FY 2024
2025-02-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.